By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Shire LLC v. Actavis South Atlantic, LLC et al.
2:08-cv-00287; filed July 24, 2008 in the Eastern District of Texas
Infringement of U.S. Patent Nos. 5,326,570 ("Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine," issued July 5, 1994) and 5,912,013 (same title, issued June 15, 1999) following a Paragraph IV certification as part of Actavis' filing of an ANDA to manufacture a generic version of Shire's Carbatrol® (carbamazepine, used to treat epilepsy and trigeminal neuralgia). View the complaint here.
AstraZeneca LP et al. v. Mylan Pharmaceuticals Inc.
1:08-cv-00453; filed July 22, 2008 in the District Court of Delaware
Infringement of U.S. Patent Nos. 6,423,340 ("Method for the Treatment of Inflammatory Bowel Diseases," issued July 23, 2002) and 5,643,602 ("Oral Composition for the Treatment of Inflammatory Bowel Diseases," issued July 1, 1997) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of AstraZeneca's Entocort® EC (budesonide, used to treat mild to moderate Crohn's disease). View the complaint here.
Cephalon Inc. et al. v. Barr Pharmaceuticals Inc. et al.
1:08-cv-00455; filed July 22, 2008 in the District Court of Delaware
Infringement of U.S. Patent Nos. 6,200,604 ("Sublingual Buccal Effervescent," issued March 13, 2001) and 6,974,590 (same title, issued December 13, 2005) following a Paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of Cephalon's Fentora® (fentanyl citrate buccal tablets, used to treat breakthrough pain in adult patients with cancer). View the complaint here.
Astellas Pharma Inc. et al. v. Impax Laboratories, Inc.
5:08-cv-03466; filed July 18, 2008 in the Northern District of California
Infringement of U.S. Patent No. 4,703,063 ("Sulfamoyl Substituted Phenethylamine Derivatives and Process of Producing Them," issued October 27, 1987) following a Paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of Astellas' Flomax® (tamsulosin hydrochloride, used to treat benign prostatic hyperplasia, sold in the U.S. by Boehringer Ingelheim Corporation. View the complaint here.
Hoffmann-La Roche Inc. v. Dr. Reddy's Laboratories, Ltd. et al.
2:08-cv-03607; filed July 18, 2008 in the District Court of New Jersey
Infringement of U.S. Patent No. 7,192,938 ("Method of Treatment Using Bisphosphonic Acid," issued March 20, 2007) following a Paragraph IV certification as part of an amendment to Dr. Reddy's ANDA to manufacture a generic version of Roche's Boniva® (150 mg once-monthly tablets) (ibandronate sodium, used to treat post-menopausal osteoporosis). View the complaint here.
Apotex Inc. v. Shire LLC
2:08-cv-03598; filed July 17, 2008 in the District Court of New Jersey
Declaratory judgment of non-infringement and invalidity of U.S. Patent Nos. 5,326,570 ("Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine," issued July 5, 1994) and 5,912,013 (same title, issued June 15, 1999) in conjunction with Apotex's filing of an ANDA to manufacture a generic version of Shire's Carbatrol® (carbamazepine, used to treat epilepsy and trigeminal neuralgia). View the complaint here.
Comments